title: [Pulmonary alterations in Hodgkin lymphoma].
abstract: Most of Hodgkin lymphoma patients survive due to combined chemo/radiotherapy. Improved survival brings long-term side effects to the front, which may determine the patients' subsequent quality of life and expected lifetime. This manuscript aims to analyze lung manifestations of Hodgkin lymphoma and treatment related pulmonary complications, demonstrated with own cases. The lung involvement in Hodgkin lymphoma is often secondary, and primary pulmonary involvement is very rare. The authors found 8-12% of lung involvement among their patients. Side effects of treatment consist of pulmonary infections in conjuction with immunosuppression, while on the other hand bleomycin and chest irradiation as part of current standard of care induced pneumonitis and fibrosis are reported. The pulmonary involvement in Hodgkin lymphoma may cause differential diagnostic difficulty. Lung involvement could modify stage and consequently treatment, and the development of side effects might determine later quality of life and expected lifetime. Therefore, identification of lung involvement is crucial.
authors.affiliation: Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.
authors.forename: Ádám
authors.initials: Á
authors.lastname: Jóna
authors.affiliation: Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.
authors.forename: Árpád
authors.initials: Á
authors.lastname: Illés
authors.affiliation: Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.
authors.forename: Katalin
authors.initials: K
authors.lastname: Szemes
authors.affiliation: Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Miltényi
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects*; D059248:Chemoradiotherapy / Q000009:adverse effects*; D003937:Diagnosis, Differential; D005355:Fibrosis / Q000209:etiology; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D008168:Lung / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology* / Q000528:radiation effects; D008171:Lung Diseases / Q000000981:diagnostic imaging / Q000209:etiology* / Q000473:pathology; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000175:diagnosis; D009894:Opportunistic Infections / Q000209:etiology; D011014:Pneumonia / Q000209:etiology; D011655:Pulmonary Embolism / Q000209:etiology; D011788:Quality of Life; D014057:Tomography, X-Ray Computed
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin
keywords: Hodgkin lymphoma; Hodgkin-lymphoma; bleomycin; chest irradiation; lung involvement; mellkasi irradiáció; második daganat; second tumor; tüdőérintettség